Table 1. Patient characteristics.
| Controls, n = 20 | NAFLD patients, n = 93 | Non-NASH patients, n = 54 | NASH patients, n = 39 | |
| Age, years | 50.6±16.8 | 51.0±11.1 | 50.2±11.3 | 52.2±10.8 |
| Male, %† | 30.0 | 51.6 | 63.0 | 35.9 |
| BMI, kg per m2 * | 22.5±2.8 | 29.4±3.8 | 29.1±3.7 | 29.8±4.0 |
| WC, cm* | 81.8±7.6 | 97.7±9.7 | 96.8±9.7 | 98.8±9.7 |
| Diabetes mellitus, %* | 0 | 59.1 | 51.9 | 69.2 |
| Hypertension, %* | 20.0 | 88.2 | 85.2 | 92.3 |
| Dyslipidemia, %* | 40.0 | 96.8 | 94.4 | 100 |
| Serum ALT, IU/L* † | 26 (22–32) | 70 (44–109) | 61 (44–93) | 86 (55–121) |
| Serum AST, IU/L* ‡ | 20 (18–27) | 41 (28–64) | 34 (25–46) | 58 (38–78) |
| Serum GGT, IU/L* † | 33 (22–45) | 75 (47–125) | 56 (40–101) | 97 (53–151) |
| Plasma M30, U/L* | 162 (103–215) | 349 (257–612) | 332 (249–534) | 435 (279–758) |
| Liver biopsy length, mm | – | 15.0±3.9 | 14.5±4.2 | 15.7±3.5 |
| Number of portal tracts | – | 8 (7–10) | 8 (6–10) | 9 (7–11) |
| Steatosis† | ||||
| 0 | – | 3.2 | 5.6 | 0 |
| 1 | – | 34.4 | 42.6 | 23.1 |
| 2 | – | 47.3 | 48.1 | 46.2 |
| 3 | – | 15.1 | 3.7 | 30.8 |
| Lobular inflammation‡ | ||||
| 0 | – | 4.3 | 7.4 | 0 |
| 1 | – | 53.8 | 81.5 | 15.4 |
| 2 | – | 38.7 | 11.1 | 76.9 |
| 3 | – | 3.2 | 0 | 7.7 |
| Ballooning‡ | ||||
| 0 | – | 14.0 | 24.1 | 0 |
| 1 | – | 60.2 | 70.4 | 46.2 |
| 2 | – | 25.8 | 5.6 | 53.8 |
| Fibrosis‡ | ||||
| 0 | – | 30.1 | 44.4 | 10.3 |
| 1 | – | 43.0 | 42.6 | 43.6 |
| 2 | – | 6.5 | 1.9 | 12.8 |
| 3 | – | 18.3 | 7.4 | 33.3 |
| 4 | – | 2.2 | 3.7 | 0 |
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; BMI, body mass index; WC, waist circumference; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase.
* Significant at p<0.001 between healthy controls and NAFLD patients.
†
Significant at p<0.05.
‡
Significant at p<0.001, between non-NASH and NASH patients.